---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-263529"
form_type: "8-K"
ticker: "OFIX"
cik: "0000884624"
company_name: "Orthofix Medical Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:47:36.729788+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Orthofix Q3 pro forma net sales up 5.7%; adj EBITDA margin expands to 12.1%

## Summary
- Pro forma net sales $203.4M, +5.7% constant currency vs Q3 2024; reported net sales $205.6M.
- Non-GAAP adj EBITDA $24.6M (12.1% margin) vs $19.2M (9.8%) prior year; seven consecutive quarters of expansion.
- U.S. Spine Fixation sales +8%, Bone Growth Therapies +6%, Global Orthopedics constant currency +6%.
- FY2025 pro forma net sales guidance narrowed to $810-814M; adj EBITDA guidance raised low end to $84-86M.
- Free cash flow positive $2.5M in Q3; positive FCF expected for full year 2025.

## SEC filing metadata
- accession: 0001193125-25-263529
- form_type: 8-K
- ticker: OFIX
- cik: 0000884624
- company_name: Orthofix Medical Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/884624/000119312525263529/0001193125-25-263529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/884624/000119312525263529/ofix-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-263529
- JSON: https://secwatch.observer/filing/0001193125-25-263529.json
- Plain text: https://secwatch.observer/filing/0001193125-25-263529.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.